For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development (including 1,375,000 for the three months ended march 31, 2026 and 2025, from related party) | 1,400,275 | -2,969,594.5* | 4,152,642 | 4,660,301 |
| General and administrative (including 69,946 and 64,433 for the three months ended march 31, 2026 and 2025, respectively, from related parties) | 891,789 | 515,778* | 648,507 | 883,727 |
| Total operating expenses | 2,292,064 | -2,453,816.5 | 4,801,149 | 5,544,028 |
| Gain from operations | -2,292,064 | 2,453,816.5 | -4,801,149 | -5,544,028 |
| Gain before income tax | -2,292,064 | 2,453,816.5* | -4,801,149 | -5,544,028 |
| Income tax provision | - | -1,712* | - | 850 |
| Net gain | -2,292,064 | 2,455,528.5 | -4,801,149 | -5,544,878 |
| Basic EPS | -0.05 | 0.066 | -0.13 | -0.15 |
| Diluted EPS | -0.05 | 0.066 | -0.13 | -0.15 |
| Basic Average Shares | 42,121,075 | 37,200,817 | 37,096,024 | 36,165,589 |
| Diluted Average Shares | 42,121,075 | 37,200,817 | 37,096,024 | 36,165,589 |
Estrella Immunopharma, Inc. (ESLAW)
Estrella Immunopharma, Inc. (ESLAW)